Showing 361 - 380 results of 173,414 for search '(( 10 ((mean decrease) OR (we decrease)) ) OR ( 5 ((mg decrease) OR (a decrease)) ))', query time: 1.55s Refine Results
  1. 361
  2. 362
  3. 363
  4. 364
  5. 365
  6. 366
  7. 367
  8. 368
  9. 369
  10. 370

    Mefunidone decreased collagen I, collagen III, α-smooth muscle actin (α-SMA) and fibronectin (FN) expression in the obstructive kidneys after UUO at 14 days. by Chunyan Liu (44864)

    Published 2015
    “…<p><b><i>A</i>.</b> Mefunidone affected collagen I (left) and collagen III (right) protein expression in the obstructed kidneys stained by immunohistochemistry (×200). …”
  11. 371
  12. 372
  13. 373

    Image2_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  14. 374

    Image1_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  15. 375
  16. 376
  17. 377

    datasheet1_Allopregnanolone Decreases Evoked Dopamine Release Differently in Rats by Sex and Estrous Stage.docx by Ana Paula S. Dornellas (9983996)

    Published 2021
    “…In females, 15 and 25 mg/kg allopregnanolone reduced dopamine release, while 7.5 mg/kg allopregnanolone was no different from vehicle. …”
  18. 378

    <i>In vivo</i> treatment with entinostat decreases Foxp3 expression in Tregs and inhibits Tregs function. by Li Shen (110858)

    Published 2012
    “…<p>BALB/c mice were treated with vehicle (0.5% methocel) or 5 mg/kg/day or 20 mg/kg/day of entinostat by gavage for 5 days. …”
  19. 379
  20. 380

    The NK1-receptor antagonist ezlopitant significantly decreases voluntary intake of non-caloric saccharin solution. by Pia Steensland (362091)

    Published 2013
    “…<p>Ezlopitant (5 and 10 mg/kg) significantly decreased consumption of the non-caloric 0.2% saccharin solution compared to vehicle. …”